|
1) Takahashi S, Tanaka T, Sakai J. New therapeutic target for metabolic syndrome: PPARdelta. Endocr J. 2007; 54: 347-57
|
|
|
|
2) Takahashi S, Tanaka T, Kodama T, et al. Peroxisome proliferator-activated receptor delta (PPARdelta), a novel target site for drug discovery in metabolic syndrome. Pharmacol Res. 2006; 53: 501-7
|
|
|
|
|
|
3) Lee CH, Chawla A, Urbiztondo N, et al. Transcriptional repression of atherogenic inflammation: modulation by PPARdelta. Science. 2003; 302: 453-7
|
|
|
|
|
|
4) Dreyer C, Krey G, Keller H, et al. Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell. 1992; 68: 879-87
|
|
|
|
|
|
5) Kliewer SA, Forman BM, Blumberg B, et al. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A. 1994; 91: 7355-9
|
|
|
|
|
|
6) Xu HE, Lambert MH, Montana VG, et al. Molecular recognition of fatty acids by pero-xisome proliferator-activated receptors. Mol Cell. 1999; 3: 397-403
|
|
|
|
|
|
7) Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eico-sanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci U S A. 1997; 94: 4312-7
|
|
|
|
|
|
8) Oliver WR Jr, Shenk JL, Snaith MR, et al. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci U S A. 2001; 98: 5306-11
|
|
|
|
|
|
9) Tanaka T, Yamamoto J, Iwasaki S, et al. Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci U S A. 2003; 100: 15924-9
|
|
|
|
|
|
10) Luquet S, Lopez-Soriano J, Holst D, et al. Peroxisome proliferator-activated receptor delta controls muscle development and oxidative capability. Faseb J. 2003; 17: 2299-301
|
|
|
|
|
|
11) Planavila A, Laguna JC, Vazquez-Carrera M. Nuclear factor-kappa B activation leads to down-regulation of fatty acid oxidation during cardiac hypertrophy. J Biol Chem. 2005; 280: 17464-71
|
|
|
|
|
|
12) Li AC, Binder CJ, Gutierrez A, et al. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma. J Clin Invest. 2004; 114: 1564-76
|
|
|
|
|
|
13) Graham TL, Mookherjee C, Suckling KE, et al. The PPARdelta agonist GW0742X reduces atherosclerosis in LDLR(-/-) mice. Atherosclerosis. 2005; 181: 29-37
|
|
|
|
|
|
14) Barish GD, Narkar VA, Evans RM. PPAR delta: a dagger in the heart of the metabolic syndrome. J Clin Invest. 2006; 116: 590-7
|
|
|
|
|